Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis

Weng,Hong; Huang,Jing‑Yu; Meng,Xiang‑Yu; Li,Sheng; Zhang,Gu‑Qin

doi:10.3892/br.2016.624

Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis

Authors:
- Hong Weng
- Jing‑Yu Huang
- Xiang‑Yu Meng
- Sheng Li
- Gu‑Qin Zhang
View Affiliations

Affiliations: Center for Evidence‑Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: March 4, 2016 https://doi.org/10.3892/br.2016.624
Pages: 595-600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of studies have suggested that the Mycobacterium vaccae (MV) vaccine as an adjunctive therapy has a positive effect in the treatment of multidrug‑resistant tuberculosis (MDR‑TB). However, the result is inconclusive. The aim of the present study was to systematically evaluate the effect and safety of MV as an adjunctive therapy in the treatment of MDR‑TB. A computerized search of PubMed, Embase, Cochrane Central Register of Controlled Trials, CBM, CNKI and VIP until October 2014 was conducted to collect the relevant studies. The main outcome measures were the sputum smear positive-turned-negative rate, the absorption rate of TB foci and the closure situation of the TB cavity. Two investigators identified the eligible studies and extracted data independently. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated and pooled using the fixed effects model. A total of 25 studies involving 2,281 patients with MDR-TB were included. The pooled OR was 3.84 (95% CI, 3.84‑4.73) for the sputum smear positive-turned-negative, 4.08 (95% CI, 3.08-5.45) for the absorption rate of TB foci, and 3.42 (95% CI, 2.68-4.37) for the closure situation of TB cavity. Therefore, MV has a significant effect as an adjunctive therapy in the treatment of MDR‑TB. However, larger scale multicenter randomized controlled trials are required to confirm this evidence for limited latent bias at present.

View Figures

View References

1	Dye C, Floyd K and Uplekar M: Global tuberculosis control: Surveillance planning financing. WHO report 2008. World Health Organization. (Geneva). 3002008.
2	Yang XY, Chen QF, Li YP and Wu SM: Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A meta-analysis. PLoS One. 6:e238262011. View Article : Google Scholar : PubMed/NCBI
3	Abou-Zeid C, Gares MP, Inwald J, Janssen R, Zhang Y, Young DB, Hetzel C, Lamb JR, Baldwin SL, Orme IM, et al: Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun. 65:1856–1862. 1997.PubMed/NCBI
4	Hernandez-Pando R, Pavön L, Arriaga K, Orozco H, Madrid-Marina V and Rook G: Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun. 65:3317–3327. 1997.PubMed/NCBI
5	Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD and Tan PL: Immunization with heat-killed Mycobacterium vaccae stimulates CD8⁺ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun. 65:4525–4530. 1997.PubMed/NCBI
6	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 339:b27002009. View Article : Google Scholar : PubMed/NCBI
7	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
8	Luo Y, Lu S and Guo S: Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi. 23:85–88. 2000.(In Chinese). PubMed/NCBI
9	Song XD, Ren YW, Zhu H, Ji Q and Xu Y: The effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis of 36 cases. Zhongguo Zong He Lin Chuang. 18:482002.(In Chinese).
10	Wu C, Yu GC and Cheng CX: Effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis of 43 cases. Zhongguo She Qu Yi Shi: Yi Xue Zhuan Ye. 6:15–16. 2004.(In Chinese).
11	Zheng XM, Li SH and Xing BC: Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao. 24:574–578. 2004.(In Chinese). PubMed/NCBI
12	Chen SQ, Liu JY and Weng LZ: Pharmacoeconomics evaluation for the treatment of Mycobacterium vaccae on multidrug-tuberculosis. Fu Jian Yi Yao Za Zhi. 27:129–131. 2005.(In Chinese).
13	Yao HB, Shang HZ, Guo L, Wang YL, Feng JM and Ma JM: The observation of the effect of the treatment of multi-drug resistant pulmonary tuberculosis with M Vaccae. Zhongguo Fang Lao Za Zhi. 27:389–392. 2005.(In Chinese).
14	Liu YH: Effect of Mycobacterium vaccae as an adjunctive therapy on multidrug resistant tuberculosis. Zhongguo Ji Ceng Yi Yao. 13:492–493. 2006.(In Chinese).
15	Wang JY and Lin DW: Effect of Mycobacterium vaccae on multidrug resistant tuberculosis. Hua Xia Yi Xue. 19:443–445. 2006.(In Chinese).
16	Lan K: Effect of Mycobacterium vaccae as an adjunctive therapy on multidrug resistant pulmonary tuberculosis. Nei Ke. 2:47–48. 2007.(In Chinese).
17	Zhao SX: Effect of Mycobacterium vaccae vaccine in treatment of multi-drug resistant tuberculosis. Lin Chuang Fei Ke Za Zhi. 13:927–928. 2008.(In Chinese).
18	Chu NH, Luo YA, Zhu LZ, Fu Y, Ye Z, Xiao H, Wang W, Yuan S, Zhang X, Lu S, et al: A controlled clinical study of long course chemotherapy regimens combined with immunopotentiator in the treatment of multi-drug resistant pulmonary tuberculosis. Zhongguo Fang Lao Za Zhi. 31:10–14. 2009.(In Chinese).
19	Gu XY: Effect of Mycobacterium vaccae as an adjunctive therapy on 70 multidrug resistant tuberculosis cases. Lin Chuang Fei Ke Za Zhi. 14:1677–1678. 2009.(In Chinese).
20	Hong Y and Lin XH: Effect of Mycobacterium vaccae vaccine plus anti-tuberculosis drugs on multi-resistant tuberculosis. Zhongguo Re Dai Yi Xue. 9:850–851. 2009.(In Chinese).
21	Wang YL: Study of microcalory united with chemotherapeutics on tuberculosis of more drugs fast. Xian Dai Zhong Xi Yi Jie He Za Zhi. 18:2362–2363. 2009.(In Chinese).
22	Xi XE, Zhang HQ and Zhang LG: Frozen-dried M. Vaccae Vavvine for therapy combined with general chemotherapy for multi-drug resistance pulmonary tuberculosis. Xin Xiang Yi Xue Yuan Xue Bao. 26:355–357. 2009.(In Chinese).
23	Liu XD: MV immune treatment of multi-drug resistant tuberculosis 32 cases of clinical curative effect observation. Gan Nan Yi Xue Yuan Xue Bao. 30:4122010.(In Chinese).
24	Mei YZ and Yang LM: Effects of Mycobacterium vaccae vaccine on multi-drug resistant pulmonary tuberculosis. Zhongguo Re Dai Yi Xue. 10:693–694. 2010.(In Chinese).
25	Zhang JD: MV with the chemotherapy drug therapy retreatment on case of multi-drug resistant tuberculosis curative effect observation. Lin Chuang Fei Ke Za Zhi. 15:1489–1490. 2010.(In Chinese).
26	Sheng GL: Clinical analysis of Vaccae combined anti-tuberculosis drugs in treatment of multidrug-resistant tuberculosis. Yi Yao Lun Tan Za Zhi. 32:37–38. 2011.(In Chinese).
27	Wang L and Jin ZD: Effect of Mycobacterium vaccae vaccine on multi-drug resistant pulmonary tuberculosis. Zhongguo She Qu Yi Shi: Yi Xue Zhuan Ye. 13:522011.(In Chinese).
28	Yang SY: Clinical analysis of Vaccae combined anti-tuberculosis drugs in treatment of 60 cases of multidrug-resistant tuberculosis. Zhongguo Yi Yao Zhi Nan. 9:105–106. 2011.(In Chinese).
29	Zhou Y: Clinical observation of mycobacterium bovis combination with chemotherapy on multidrug-resistant mycobacterium. Chong Qin Yi Xue. 40:341–342. 2011.(In Chinese).
30	Chen YJ: Chemical joint MV clinical research for the treatment of senile multi-drug resistant tuberculosis. Zhong Wai Yi Xue Yan Jiu. 10:442012.(In Chinese).
31	Yin LS, Zhu M and Zhou M: Clinical observation on buqin tablet combined with Western medicine for 17 cases of multidrug-resistant tuberculosis. Zhong Yi Za Zhi. 53:669–672. 2012.(In Chinese).
32	Zhang XL and Huang D: Effects of cellular immunity improvement on chemotherapy efficacy and prognosis of patients with multidrug-resistant tuberculosis. Shi Yong Yi Xue Za Zhi. 29:1964–1966. 2013.(In Chinese).
33	Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V and Zignol M: Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur Respir J. 39:1425–1431. 2012. View Article : Google Scholar : PubMed/NCBI
34	Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K and Raviglione M: Surveillance of anti-tuberculosis drug resistance in the world: An updated analysis, 2007–2010. Bull World Health Organ. 90:111–119D. 2012. View Article : Google Scholar : PubMed/NCBI
35	Stanford JL, Bahr GM, Rook GA, Shaaban MA, Chugh TD, Gabriel M, al-Shimali B, Siddiqui Z, Ghardani F, Shahin A, et al: Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle. 71:87–93. 1990. View Article : Google Scholar : PubMed/NCBI
36	World Health Organization (WHO): Tuberculosis research and development: Report of a WHO meeting. WHO, Geneva: 1991.
37	Stanford JL, Stanford CA, Grange JM, Lan NN and Etemadi A: Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? Respir Med. 95:444–447. 2001. View Article : Google Scholar : PubMed/NCBI
38	Schulz KF, Chalmers I, Hayes RJ and Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273:408–412. 1995. View Article : Google Scholar : PubMed/NCBI
39	Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P and Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 352:609–613. 1998. View Article : Google Scholar : PubMed/NCBI
40	Jüni P, Altman DG and Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 323:42–46. 2001. View Article : Google Scholar : PubMed/NCBI